Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
“BCC Research highlights how protein therapeutics, cell-free systems, high-throughput technologies, personalized medicine and improved expression vectors are shaping market growth.”
May 18, 2026
The global protein synthesis research market is poised for substantial expansion, with BCC Research's latest analysis revealing accelerating growth driven by unprecedented investment in cell and gene therapy (CGT) research and rising prevalence of chronic diseases. The comprehensive study, 2025 Protein Synthesis Research Review, positions this as a critical sector for biotechnology investors as therapeutic breakthroughs advance toward commercialization.
KEY FINDINGS
Market expansion fueled by CGT momentum: Increasing investments and R&D funding in cell and gene therapy research are creating substantial demand for protein synthesis tools and technologies.
North American market leadership: North America commands 42.8% of the global market share, driven by robust biotech infrastructure, significant venture capital deployment, and supportive regulatory frameworks.
Chronic disease burden drives demand: Growing prevalence of chronic and degenerative diseases is expanding the addressable patient population, creating sustained demand for protein synthesis research tools.
Healthcare spending acceleration: Rising healthcare expenditure and government support, particularly through initiatives like the CHIPS and Science Act and European Horizon programs, are providing sustained funding.
Asia-Pacific infrastructure expansion: Advancing biomedicine research infrastructure in Asia-Pacific represents a significant growth vector, with countries like China and South Korea investing heavily in biotechnology capabilities.
Blue-chip competitive landscape: Market leaders include Alnylam Pharmaceuticals, Sarepta Therapeutics, Ionis Pharmaceuticals, Biogen, AstraZeneca, Novartis AG, Thermo Fisher Scientific, Merck KGaA, FUJIFILM Corp., Lonza, GenScript, and WuXi.
MARKET DRIVERS
The protein synthesis research market is experiencing structural tailwinds from multiple directions. The convergence of increased CGT investment with advancing disease understanding is creating a compelling growth environment. Strong pipeline activity in late-stage therapies awaiting regulatory approval provides near-term commercial catalysts, while expanding healthcare budgets ensure sustained research funding.
INVESTMENT CONSIDERATIONS
The protein synthesis research market presents a compelling opportunity for investors seeking exposure to the biotechnology megatrend. Key investment themes include CRISPR gene editing technologies, CAR T-cell therapies with remote-control functions, off-the-shelf cell and gene therapy products, and MRI-guided intracranial AAV delivery gene therapy.
For more information or to download the report, visit https://www.bccresearch.com/market-research/biotechnology/protein-synthesis-research-review.html
2025 Protein Synthesis Research Review( BIO264B )
Publish Date: Apr 2026
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
Reports from Cell Biology
Recent News
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum